Publications

Scientific contributions highlighting the impact of Diatech Pharmacogenetics technologies in diagnostics.

Filter

Year

All years 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2008

Product line

All product lines Easy Easy PGX Helix Microsatelliti Myriapod Myriapod NGS Realquant Response

24.11.2014

Helix

Improved Stool DNA Integrity Method for Early Colorectal Cancer Diagnosis. Cancer Epidemiology, Biomarkers & Prevention

11.10.2014

Response

EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition. Journal of Experimental & Clinical Cancer Research

05.08.2014

Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence. Journal of Experimental & Clinical Cancer Research

04.08.2014

Response

Prevalence and Clinicopathologic Correlates of O6-Methylguanine-DNA Methyltransferase Methylation Status in Patients With Triple-Negative Breast Cancer Treated Preoperatively by Alkylating Drugs. Clinical Breast Cancer

01.07.2014

Response

Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience. Cancer Cytopathology

01.06.2014

Myriapod, Response

COMPARISON OF A NEW MULTIPLEXED MULTIGENE APPROACH WITH PYROSEQUENCING IN DIAGNOSTIC MOLECULAR BIOLOGY OF COLORECTAL CANCER (CRC). Annals of Oncology

05.05.2014

Response

Immunohistochemistry for BRAF(V600E) Antibody VE1 Performed in Core Needle Biopsy Samples Identifies Mutated Papillary Thyroid Cancers. Hormone and Metabolic Research

05.05.2014

Response

KRAS and BRAF genotyping of synchronous colorectal carcinomas. Oncology Letters

15.04.2014

Response

Synchronous pleural and peritoneal malignant mesothelioma: a case report and review of literature. International Journal of Clinical & Experimental Pathology

14.04.2014

Response

Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Operable Breast Cancer. Journal of Clinical Oncology

Your next step starts here. Fill out the form and talk to us